Globus Medical, Inc. (GMED)
USD 81.78
(-1.97%)
USD 81.78
(-1.97%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.02 Billion USD | 34.41% |
| 2022 | 759.11 Million USD | 5.6% |
| 2021 | 718.87 Million USD | 25.77% |
| 2020 | 571.57 Million USD | -5.59% |
| 2019 | 605.39 Million USD | 9.36% |
| 2018 | 553.55 Million USD | 14.01% |
| 2017 | 485.52 Million USD | 13.1% |
| 2016 | 429.28 Million USD | 4.21% |
| 2015 | 411.95 Million USD | 13.32% |
| 2014 | 363.51 Million USD | 8.8% |
| 2013 | 334.11 Million USD | 7.5% |
| 2012 | 310.79 Million USD | 18.32% |
| 2011 | 262.68 Million USD | 12.08% |
| 2010 | 234.37 Million USD | 10.17% |
| 2009 | 212.73 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 335.5 Million USD | -4.43% |
| 2024 Q3 | 355.19 Million USD | -4.36% |
| 2024 Q2 | 339.94 Million USD | 1.32% |
| 2023 Q4 | 351.04 Million USD | 41.41% |
| 2023 FY | 1.02 Billion USD | 34.41% |
| 2023 Q1 | 205.86 Million USD | 0.96% |
| 2023 Q2 | 215.14 Million USD | 4.51% |
| 2023 Q3 | 248.24 Million USD | 15.39% |
| 2022 Q2 | 195.17 Million USD | 13.88% |
| 2022 Q4 | 203.9 Million USD | 8.09% |
| 2022 Q3 | 188.65 Million USD | -3.34% |
| 2022 FY | 759.11 Million USD | 5.6% |
| 2022 Q1 | 171.38 Million USD | -8.95% |
| 2021 Q2 | 187.17 Million USD | 8.62% |
| 2021 Q4 | 188.22 Million USD | 9.97% |
| 2021 FY | 718.87 Million USD | 25.77% |
| 2021 Q1 | 172.31 Million USD | -0.16% |
| 2021 Q3 | 171.16 Million USD | -8.55% |
| 2020 Q1 | 141.71 Million USD | -13.01% |
| 2020 FY | 571.57 Million USD | -5.59% |
| 2020 Q4 | 172.58 Million USD | 8.54% |
| 2020 Q3 | 159 Million USD | 61.79% |
| 2020 Q2 | 98.27 Million USD | -30.65% |
| 2019 Q3 | 150.82 Million USD | 0.19% |
| 2019 FY | 605.39 Million USD | 9.36% |
| 2019 Q1 | 141.1 Million USD | -5.92% |
| 2019 Q2 | 150.54 Million USD | 6.69% |
| 2019 Q4 | 162.9 Million USD | 8.01% |
| 2018 FY | 553.55 Million USD | 14.01% |
| 2018 Q4 | 149.98 Million USD | 14.15% |
| 2018 Q2 | 135.74 Million USD | -0.51% |
| 2018 Q1 | 136.44 Million USD | 0.93% |
| 2018 Q3 | 131.38 Million USD | -3.21% |
| 2017 Q1 | 120.2 Million USD | 6.77% |
| 2017 Q2 | 115.19 Million USD | -4.17% |
| 2017 Q3 | 114.94 Million USD | -0.21% |
| 2017 FY | 485.52 Million USD | 13.1% |
| 2017 Q4 | 135.17 Million USD | 17.6% |
| 2016 Q1 | 107.62 Million USD | 0.09% |
| 2016 Q3 | 104.19 Million USD | -0.42% |
| 2016 Q2 | 104.63 Million USD | -2.78% |
| 2016 Q4 | 112.58 Million USD | 8.05% |
| 2016 FY | 429.28 Million USD | 4.21% |
| 2015 Q1 | 99.49 Million USD | 2.02% |
| 2015 Q2 | 100.99 Million USD | 1.5% |
| 2015 Q3 | 103.94 Million USD | 2.92% |
| 2015 Q4 | 107.52 Million USD | 3.45% |
| 2015 FY | 411.95 Million USD | 13.32% |
| 2014 Q2 | 86.99 Million USD | -2.15% |
| 2014 Q4 | 97.52 Million USD | 8.24% |
| 2014 Q3 | 90.1 Million USD | 3.58% |
| 2014 Q1 | 88.89 Million USD | 0.48% |
| 2014 FY | 363.51 Million USD | 8.8% |
| 2013 FY | 334.11 Million USD | 7.5% |
| 2013 Q3 | 81.87 Million USD | -0.46% |
| 2013 Q4 | 88.47 Million USD | 8.06% |
| 2013 Q1 | 81.52 Million USD | 0.67% |
| 2013 Q2 | 82.24 Million USD | 0.89% |
| 2012 Q1 | 76.32 Million USD | 11.42% |
| 2012 FY | 310.79 Million USD | 18.32% |
| 2012 Q4 | 80.97 Million USD | 6.7% |
| 2012 Q3 | 75.89 Million USD | -2.2% |
| 2012 Q2 | 77.59 Million USD | 1.67% |
| 2011 Q4 | 68.5 Million USD | 2.05% |
| 2011 Q2 | 63.66 Million USD | 0.45% |
| 2011 FY | 262.68 Million USD | 12.08% |
| 2011 Q1 | 63.38 Million USD | 0.0% |
| 2011 Q3 | 67.12 Million USD | 5.44% |
| 2010 FY | 234.37 Million USD | 10.17% |
| 2009 FY | 212.73 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott Laboratories | 22.13 Billion USD | 95.39% |
| Allurion Technologies Inc. | 41.49 Million USD | -2358.737% |
| Artivion, Inc. | 229.17 Million USD | -345.205% |
| Avanos Medical, Inc. | 379.7 Million USD | -168.713% |
| Butterfly Network, Inc. | 16.85 Million USD | -5953.049% |
| Butterfly Network, Inc. | 16.85 Million USD | -5953.049% |
| Bio-Rad Laboratories, Inc. | 1.43 Billion USD | 28.717% |
| Boston Scientific Corporation | 9.89 Billion USD | 89.689% |
| Perspective Therapeutics, Inc. | 1.63 Million USD | -62341.983% |
| CONMED Corporation | 643.06 Million USD | -58.662% |
| Edwards Lifesciences Corporation | 4.62 Billion USD | 77.939% |
| Paragon 28, Inc. | 172.79 Million USD | -490.483% |
| Glaukos Corporation | 239.13 Million USD | -326.662% |
| Inspire Medical Systems, Inc. | 528.22 Million USD | -93.157% |
| Integer Holdings Corporation | 418.28 Million USD | -143.923% |
| Medtronic plc | 19.45 Billion USD | 94.755% |
| Nevro Corp. | 290.06 Million USD | -251.755% |
| Owlet, Inc. | 22.58 Million USD | -4417.209% |
| Penumbra, Inc. | 682.64 Million USD | -49.463% |
| Vicarious Surgical Inc. | -1.85 Million USD | 55132.47% |
| Smith & Nephew plc | 3.7 Billion USD | 72.432% |
| Sonendo, Inc. | 10.72 Million USD | -9415.967% |
| STERIS plc | 2.23 Billion USD | 54.328% |
| Stryker Corporation | 13.05 Billion USD | 92.186% |
| Vapotherm, Inc. | 28.28 Million USD | -3507.474% |
| Zimmer Biomet Holdings, Inc. | 5.31 Billion USD | 80.787% |